Uveitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035

Uveitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035

Report Format: PDF+Excel | Report ID: SR112025A32958

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2    Top-Down Approach
2.5    Forecasting Methodology

3    Executive Summary

4 Uveitis - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (​2019-2024​) and Forecast (​2025-2035​)
4.4 Market Overview (​2019-2024​) and Forecast (​2025-2035​)
4.5 Competitive Intelligence

5 Uveitis - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Uveitis - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (​2019-2024​) 
7.2.2 Epidemiology Forecast (​2025-2035​)
7.2.3 Epidemiology by Age (​2019-2035​)
7.2.4 Epidemiology by Gender (​2019-2035​)
7.2.5 Epidemiology by Type (​2019-2035​)
7.2.6 Diagnosed Cases (​2019-2035​)
7.2.7 Patient Pool/Treated Cases (​2019-2035​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (​2019-2024​)
7.3.2 Epidemiology Forecast (​2025-2035​)
7.3.3 Epidemiology by Age (​2019-2035​)
7.3.4 Epidemiology by Gender (​2019-2035​)
7.3.5 Epidemiology by Type (​2019-2035​)
7.3.6 Diagnosed Cases (​2019-2035​)
7.3.7 Patient Pool/Treated Cases (​2019-2035​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (​2019-2024​)
7.4.2 Epidemiology Forecast (​2025-2035​)
7.4.3 Epidemiology by Age (​2019-2035​)
7.4.4 Epidemiology by Gender (​2019-2035​)
7.4.5 Epidemiology by Type (​2019-2035​)
7.4.6 Diagnosed Cases (​2019-2035​)
7.4.7 Patient Pool/Treated Cases (​2019-2035​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (​2019-2024​)
7.5.2 Epidemiology Forecast (​2025-2035​)
7.5.3 Epidemiology by Age (​2019-2035​)
7.5.4 Epidemiology by Gender (​2019-2035​)
7.5.5 Epidemiology by Type (​2019-2035​)
7.5.6 Diagnosed Cases (​2019-2035​)
7.5.7 Patient Pool/Treated Cases (​2019-2035​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (​2019-2024​)
7.6.2 Epidemiology Forecast (​2025-2035​)
7.6.3 Epidemiology by Age (​2019-2035​)
7.6.4 Epidemiology by Gender (​2019-2035​)
7.6.5 Epidemiology by Type (​2019-2035​)
7.6.6 Diagnosed Cases (​2019-2035​)
7.6.7 Patient Pool/Treated Cases (​2019-2035​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (​2019-2024​)
7.7.2 Epidemiology Forecast (​2025-2035​)
7.7.3 Epidemiology by Age (​2019-2035​)
7.7.4 Epidemiology by Gender (​2019-2035​)
7.7.5 Epidemiology by Type (​2019-2035​)
7.7.6 Diagnosed Cases (​2019-2035​)
7.7.7 Patient Pool/Treated Cases (​2019-2035​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (​2019-2024​)
7.8.2 Epidemiology Forecast (​2025-2035​)
7.8.3 Epidemiology by Age (​2019-2035​)
7.8.4 Epidemiology by Gender (​2019-2035​)
7.8.5 Epidemiology by Type (​2019-2035​)
7.8.6 Diagnosed Cases (​2019-2035​)
7.8.7 Patient Pool/Treated Cases (​2019-2035​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (​2019-2024​)
7.9.2 Epidemiology Forecast (​2025-2035​)
7.9.3 Epidemiology by Age (​2019-2035​)
7.9.4 Epidemiology by Gender (​2019-2035​)
7.9.5 Epidemiology by Type (​2019-2035​)
7.9.6 Diagnosed Cases (​2019-2035​)
7.9.7 Patient Pool/Treated Cases (​2019-2035​)

8 Uveitis Treatment - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Uveitis Treatment - Unmet Needs

10 Uveitis Treatment - Key Endpoints of Treatment

11 Uveitis Treatment - Marketed Products
11.1 List of Uveitis Treatment - Marketed Drugs Across the Top 7 Markets
11.1.1 Hyrimoz (adalimumab-adaz) - Sandoz
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Clinical Trial Results
11.1.1.4 Safety and Efficacy
11.1.1.5 Regulatory Status
11.1.2 Humira - AbbVie
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Clinical Trial Results
11.1.2.4 Safety and Efficacy
11.1.2.5 Regulatory Status
11.1.3 YUFLYMA (adalimumab-aaty) - CELLTRION USA
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Clinical Trial Results
11.1.3.4 Safety and Efficacy
11.1.3.5 Regulatory Status
11.1.4 YUTIQ (fluocinolone acetonide intravitreal implant) - EyePoint Pharmaceuticals
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Clinical Trial Results
11.1.4.4 Safety and Efficacy
11.1.4.5 Regulatory Status
11.1.5 Durezol (difluprednate ophthalmic emulsion) 0.05% - Alcon Laboratories
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Clinical Trial Results
11.1.5.4 Safety and Efficacy
11.1.5.5 Regulatory Status

Complete list to be provided in the final report.

12 Uveitis Treatment - Pipeline Products
12.1 List of Uveitis Treatment Pipeline Drugs Across the Top 7 Markets
12.1.1 Brepocitinib - Priovant Therapeutics 
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Barcitinib - Eli Lilly and Company
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 TRS01 (Dazdotuftide) - Tarsier Pharma
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Izokibep - Affibody/ACELYRIN
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status

Complete list to be provided in the final report.

13 Uveitis Treatment - Attribute Analysis of Key Marketed and Pipeline Drugs

14 Uveitis Treatment – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Uveitis Treatment Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Uveitis Treatment - Market Size 
15.2.1.1 Market Size (​2019-2024​)
15.2.1.2 Market Forecast (​2025-2035​)
15.2.2 Uveitis Treatment - Market Size by Therapies 
15.2.2.1 Market Size by Therapies (​2019-2024​)
15.2.2.2 Market Forecast by Therapies (​2025-2035​)
15.3 Market Scenario - United States
15.3.1 Uveitis Treatment - Market Size
15.3.1.1 Market Size (​2019-2024​)
15.3.1.2 Market Forecast (​2025-2035​)
15.3.2 Uveitis Treatment- Market Size by Therapies
15.3.2.1 Market Size by Therapies (​2019-2024​) 
15.3.2.2 Market Forecast by Therapies (​2025-2035​)
15.3.3 Uveitis Treatment- Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Uveitis Treatment - Market Size
15.4.1.1 Market Size (​2019-2024​)
15.4.1.2 Market Forecast (​2025-2035​)
15.4.2 Uveitis Treatment- Market Size by Therapies
15.4.2.1 Market Size by Therapies (​2019-2024​) 
15.4.2.2 Market Forecast by Therapies (​2025-2035​)
15.4.3 Uveitis Treatment- Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Uveitis Treatment - Market Size
15.5.1.1 Market Size (​2019-2024​)
15.5.1.2 Market Forecast (​2025-2035​)
15.5.2 Uveitis Treatment- Market Size by Therapies
15.5.2.1 Market Size by Therapies (​2019-2024​)
15.5.2.2 Market Forecast by Therapies (​2025-2035​)
15.5.3 Uveitis Treatment- Access and Reimbursement Overview 
15.6 Market Scenario – United Kingdom
15.6.1 Uveitis Treatment - Market Size
15.6.1.1 Market Size (​2019-2024​)
15.6.1.2 Market Forecast (​2025-2035​)
15.6.2 Uveitis Treatment- Market Size by Therapies
15.6.2.1 Market Size by Therapies (​2019-2024​)
15.6.2.2 Market Forecast by Therapies (​2025-2035​)
15.6.3 Uveitis Treatment- Access and Reimbursement Overview 
15.7 Market Scenario – Italy
15.7.1 Uveitis Treatment - Market Size
15.7.1.1 Market Size (​2019-2024​)
15.7.1.2 Market Forecast (​2025-2035​)
15.7.2 Uveitis Treatment- Market Size by Therapies 
15.7.2.1 Market Size by Therapies (​2019-2024​)
15.7.2.2 Market Forecast by Therapies (​2025-2035​) 
15.7.3 Uveitis Treatment- Access and Reimbursement Overview 
15.8 Market Scenario - Spain
15.8.1 Uveitis Treatment - Market Size
15.8.1.1 Market Size (​2019-2024​)
15.8.1.2 Market Forecast (​2025-2035​)
15.8.2 Uveitis Treatment- Market Size by Therapies
15.8.2.1 Market Size by Therapies (​2019-2024​)
15.8.2.2 Market Forecast by Therapies (​2025-2035​)
15.8.3 Uveitis Treatment- Access and Reimbursement Overview 
15.9 Market Scenario - Japan
15.9.1 Uveitis Treatment - Market Size
15.9.1.1 Market Size (​2019-2024​)
15.9.1.2 Market Forecast (​2025-2035​)
15.9.2 Uveitis Treatment- Market Size by Therapies
15.9.2.1 Market Size by Therapies (​2019-2024​)
15.9.2.2 Market Forecast by Therapies (​2025-2035​)
15.9.3 Uveitis Treatment - Access and Reimbursement Overview 

16 Uveitis Treatment - Recent Events and Inputs From Key Opinion Leaders

17 Uveitis Treatment Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Uveitis – Strategic Recommendations

19 Appendix

Uveitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035
Purchase Options Discount
Offer
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials